Metris Therapeutics Ltd.
This article was originally published in Start Up
Existing drug therapies for endometriosis, including drugs that block estrogen and GnRH agonists bear troubling side effects. Metris Therapeutics hopes to avoid these by taking a different path to the disease. The company's founders were among the first to identfiy increased levels of vascular endothelial growth factor (VEGF) in the peritoneal fluid of women with endometriosis. Metris has therfore set out to develop a product to block VEGF's action.
You may also be interested in...
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.
COVID-19 has triggered a dramatic shift toward virtual consultations and telemedicine, encouraged by more relaxed regulations and payer support.
As the global shut-down caused by the coronavirus pandemic continues, sponsors are rushing to adapt clinical trials that can move to partial or completely remote monitoring, allowing patients to remain in their homes but continue to participate in studies. And the outbreak may have another silver lining for the biopharma industry, a chance to rebuild its reputation.